Davangere P. Devanand, MBBS, MD

Board Certifications: 
Geriatric Psychiatry, Psychiatry
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Age-Related Cognitive Decline, Alzheimer's Disease, Depression

Academic Appointments

  • Professor of Psychiatry (in Neurology and in the Gertrude H. Sergievsky Center) at CUMC

Administrative Titles

  • Director of Geriatric Psychiatry

Dr. D. P. Devanand is Professor of Psychiatry and Neurology at the Columbia University Medical Center. He completed medical school at Christian Medical College, Vellore, in India, and trained in psychiatry at the National Institute of Mental Health and Neurosciences, Bangalore, India.

He completed psychiatry residency training at S.U.N.Y. Upstate Medical Center, Syracuse, NY, and Yale University School of Medicine in New Haven, CT. He then did a clinical research fellowship in Biological Psychiatry at Columbia University, and has continued on the faculty at Columbia University since 1987. Currently, he is Director of the DIvision of Geriatric Psychiatry, Co-Director of the Memory Disorders Center, and Co-Director of the Adult and Late Life Depression Clinic at the New York State Psychiatric Institute. His research studies involve Alzheimer’s disease and geriatric depression.

His research helped to define the clinical features and treatment response in elderly patients with dysthymic disorder, a chronic depressive illness. He pioneered studies on the interface between depression and cognitive impairment in the elderly, and is well-known for his research into early diagnostic markers of Alzheimer’s disease and the treatment of psychosis and agitation in this disorder. He has published research articles in major journals including a landmark study on antipsychotic discontinuation in Alzheimer’s disease in the New England Journal of Medicine, and articles in several journals including JAMA, Annals of Neurology, Neurology, Archives of General Psychiatry, and American Journal of Psychiatry. He has been principal investigator on several research grants from the National Institute of Aging and the National Institute of Mental Health. He has also been funded by the Department of Defense, Alzheimer’s Association, NARSAD, and the Dana Foundation.

He has received the International Psychogeriatric Association Research Award, the American Association of Geriatric Psychiatry Distinguished Investigator Award, and the American Psychiatric Association Jack Weinberg Memorial Award in geriatric psychiatry. He has published over 275 research papers and articles, and is the author of three books.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:
646-774-8658
New Patients:
646-774-8658
Existing Patients:
646-774-8658

Location(s)

CUMC/Herbert Pardes Building of the New York State Psychiatric Institute
1051 Riverside Drive
New York, NY 10032
Primary

Insurance Accepted

UnitedHealthcare

  • Behavioral Health Columbia University Employee Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • State University of New York
  • Residency: State University of New York - Downstate Medical Center
  • Residency: Yale University Hospital

Board Certifications

  • Geriatric Psychiatry
  • Psychiatry

Honors & Awards

2001 Distinguished Scientist Award, Indo-American Psychiatric Association
2003-present: listed in Best Doctors in America, Best Doctors in New York
2014 American Psychiatric Association Jack Weinberg Memorial Award in Geriatric Psychiatry
2015 American Association of Geriatric Psychiatry Distinguished Investigator Award

NY Top Doctor

Research

Research interests include treatment strategies for mild cognitive impairment and Alzheimer's disease, including treatment of psychosis and agitation in these disorders. Other interests include early diagnostic markers of Alzheimer's disease, and the interface between depression and cognitive impairment.

1) Study of olfactory identification deficits in the prediction of response to treatment with FDA-approved cholinesterase inhibitors in patients with mild cognitive impairment and mild to moderate Alzheimer's disease.

2) Study of low dose lithium to treat patients with Alzheimer's disease who develop symptoms of agitation, aggression, delusions or hallucinations.

Both studies are funded by the National Institute of Aging, a branch of the National Institutes of health.

Research Interests

  • Neuropsychiatry/Cognitive Disorders

Grants

OLFACTORY IMPAIRMENT IN OFFSPRING STUDY OF RACIAL DISPARITIES IN ALZHEIMERS DISEASE (Federal Gov)

Sep 1 2018 - May 31 2023

TESTING OLFACTION IN PRIMARY CARE TO DETECT ALZHEIMER S DISEASE AND OTHER DEMENTIAS (TOPAD) (Federal Gov)

Sep 30 2017 - May 31 2022

ANTI-VIRAL THERAPY IN ALZHEIMER S DISEASE (Federal Gov)

Sep 15 2017 - May 31 2022

COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT (Federal Gov)

Jul 15 2017 - Apr 30 2022

OLFACTORY DEFICITS AND DONEPEZIL TREATMENT IN COGNITIVELY IMPAIRED ELDERLY (Federal Gov)

Jun 15 2013 - May 31 2019

PREDICTORS OF SEVERITY IN ALZHEIMER S DISEASE (Federal Gov)

Sep 1 2011 - May 31 2017

LOW-DOSE LITHIUM FOR THE TREATMENT OF BEHAVIORAL SYMPTOMS IN FTD (Private)

Apr 1 2016 - Mar 31 2017

CENTER OF EXCELLENCE IN ALZHEIMER DISEASE (NYS) (NY State Gov)

Jul 1 2016 - Feb 28 2017

NEUROPHYSIOLOGICAL BIOMARKERS FOR AD DRUG DEVELOPMENT (Private)

Jan 15 2015 - Jan 15 2016

OLFACTORY DEFICITS IN MCI AS PREDICTOR OF IMPROVED COGNITION ON DONEPEZIL (Federal Gov)

Apr 1 2012 - Mar 31 2015

PILOT COMBINATION TRIAL OF MILD COGNITIVE IMPAIRMENT WITH DEPRESSION (Federal Gov)

Sep 1 2011 - Aug 31 2014

QUESTIONABLE DEMENTIA: COURSE AND PREDICTORS OF OUTCOME (Federal Gov)

Mar 1 2000 - May 31 2014

VASCULAR DEPRESSION IN AA: PHENOMENOLOGY, TREATMENT, AND COURSE OF ILLNESS (Federal Gov)

Jul 1 2010 - Jun 30 2013

IN VIVO PET IMAGING OF MILD COGNITIVE IMPAIRMENT, EARLY ALZHEIMER''S DISEASE, OTHER DEMENTIAS AND HEALTHY ELDERLY... (Private)

Mar 1 2006 - Apr 30 2008

Selected Publications

  • Devanand DP, Pradhaban G, Khandji A, Tabert MH, De Santi S, Segal S, Liu X, Pelton GH, Honig L, Mayeux R, Stern Y, de Leon, M: Hippocampal and entorhinal atrophy in the prediction of MCI conversion to Alzheimer’s disease. Neurology 2007;68: 828-836
  • Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH: Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biological Psychiatry 2008;64: 871-879
  • Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B: Relapse risk after discontinuation of risperidone in Alzheimer’s disease. New England Journal of Medicine 2012;367: 1497-1507
  • Devanand DP.  Dysthymic disorder in the elderly population.  International Psychogeriatrics 26:39-48, 2014.
  • Devanand DP.  Whatever happened to new treatments for Azheimer's disease?  Journal of Clinical Psychiatry 75(7):775-6, 2014.
  • Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Masurkar A, Stern Y, Mayeux R, Doty RL. Olfactory identification deficits and increased mortality in the community.  Annals of Neurology 78:401-411, 2015.
  • Devanand DP, Lee S, Manly JJ, Andrews HA, Schupf N, Doty RL, Stern Y, Zahodne LB, Louis E, Mayeux R.  Olfactory deficits predict cognitive decline and Alzheimer’s dementia in an urban community.  Neurology 84(2):182-189, 2015.